EJC新闻聚焦——2011年8月

This months’ EJC News Focus explores why researchers need to start using a common language to describe toxicities in phase I trials. The principles underlying early research were devised decades ago to evaluate toxicity associated with chemotherapy. But novel targeted therapies often have quite different side effect profiles, and may be taken for months or years on end. In order to ensure that the agents most likely to succeed are selected for further research, Jean-Charles Soria, EJC’s Drug Development Editor, says it is time for a new consensus on how to assess toxicities.